Genetic Risk Profiling in Prostate Cancer: Patient and Provider Perspectives

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This qualitative, observational study interviews patients who have received genetic risk profiling for prostate cancer and the healthcare professionals who delivered the results. It aims to understand how results are perceived and used in clinical practice, including potential benefits, limitations, and practicalities of implementation. The findings will inform future research and help shape how genetic risk information could be integrated into routine care. The study seeks diverse input from people of different ages, ethnicities, and risk levels, and from various clinical settings within the participating sites.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals assigned male at birth who are aged 18 and over and who have capacity to consent
* Patients who have undergone genetic risk profiling for prostate cancer and have received their results
* Individuals from diverse backgrounds (age, ethnicity, risk status, etc)
* Healthcare providers who have delivered a genetic risk profiling result for prostate cancer

Exclusion Criteria:

* Individuals who lack capacity to consent
* Individuals deemed unsuitable to recruit based on their poor performance status or current medical condition

Where it's running

• The Royal Marsden Hospital (Sutton and Chelsea)
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Elizabeth Bancroft, RN PhD — The Royal Marsden NHS Foundation Trust / The Institute of Cancer Research
• Study coordinator: Tarryn Shaw, MSc
• Email: tarryn.shaw@rmh.nhs.uk
• Phone: 020 8661 3375

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer

  This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.

  Recruiting Niguarda Hospital · Milan, Lombardy · NCT07879820

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer

  This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.

  Recruiting at 8 sites Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Benidorm, Alicante and 9 other locations · NCT07860528

• Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence

  This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.

  Recruiting Phase 2 University Hospital Tuebingen · Heidelberg, Baden-Wurttemberg and 3 other locations · NCT07860047

• Lutetium-177 Ludotadipep for advanced prostate cancer

  This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.

  Recruiting at 7 sites Phase 3 FutureChem · Gyeonggi-do and 7 other locations · NCT07853209

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.